Top Suppliers:I want be here
Related CAS#:
145525-41-3 207844-01-7
1266354-02-2 145375-43-5
147526-32-7 1327-39-5
5631-00-5 12172-85-9
15245-12-2 12431-81-1
1241287-72-8 1153490-93-7
1219574-40-9 1156736-11-6
1156861-14-1 1235027-80-1
1156738-04-3 1171878-41-3
1153248-06-6 1156255-13-8

145525-41-3

145525-41-3 structure
145525-41-3 structure
  • Name: Mitiglinide (Calcium)
  • Chemical Name: Calcium 2-benzyl-4-((3aR,7aS)-hexahydro-1H-isoindol-2(3H)-yl)-4-oxobutanoate
  • CAS Number: 145525-41-3
  • Molecular Formula: C19H24NO3Ca0.5
  • Molecular Weight: 334.44
  • Catalog: API Hormone and endocrine-regulating drugs Pancreatic hormones and other blood sugar regulating drugs
  • Create Date: 2018-02-18 08:00:00
  • Modify Date: 2025-08-26 21:17:13
  • Mitiglinide(KAD-1229; S21403) is a drug for the treatment of type 2 diabetes; it is a highly selective KATP channel antagonist. IC50 value:Target: KATP channelMitiglinide is a hypoglycemic agent that closes adenosine triphosphate (ATP)-sensitive potassium channels (KATP channel s) in the pancreatic β-islet cells. Mitiglinide stimulates insulin secretion by stimulating Ca2+ influx.
Name Calcium 2-benzyl-4-((3aR,7aS)-hexahydro-1H-isoindol-2(3H)-yl)-4-oxobutanoate
Synonyms Mitiglinide
Mitiglinide calcium
MFCD08458378
(aS,3aR,7aS)-Octahydro-g-oxo-a-(phenylmethyl)-2H-isoindole-2-butanoic acid calcium salt
[2(S)-cis]-Octahydro-g-oxo-a-(phenylmethyl)-2H-isoindole-2-butanoic acid calclium salt
Mitiglinide hemicalcium salt
Mitiglinide (Calcium)
Description Mitiglinide(KAD-1229; S21403) is a drug for the treatment of type 2 diabetes; it is a highly selective KATP channel antagonist. IC50 value:Target: KATP channelMitiglinide is a hypoglycemic agent that closes adenosine triphosphate (ATP)-sensitive potassium channels (KATP channel s) in the pancreatic β-islet cells. Mitiglinide stimulates insulin secretion by stimulating Ca2+ influx.
Related Catalog
References

[1]. Kiyoshi Ichikawa, Tokuhisa Yamato, Kazuma Ojima, et al. Effect Of Kad-1229, A Novel Hypoglycaemic Agent, On Plasma Glucose Levels After Meal Load In Type 2 Diabetic Rats. Clinical and Experimental Pharmacology and Physiology. 2002, 29 (5-6): 423-427

[2]. Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.European Journal of Pharmacology.2001, 431(1):119

[3]. Kiyoshi Ichikawa, Kazuyasu Maruyama, Makoto Murakami, et al. Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent. European Journal of Pharmacology.2001, 3(23): 331-338

[4]. Ohnota H, Kitamura T, Kinukawa M, et al. A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Japanese Journal of Phar

[5]. Hideo Mogamia, Hiroshi Shibataa, Romi Nobusawaa, et al. Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic β-cell line, MIN 6 cell.. European Journal of Pharmacology: Molecular Pharmacology. 1994, 269(3): 293-29
Density 1.175
Boiling Point 519.6ºC at 760 mmHg
Melting Point 146-148ºC
Molecular Formula C19H24NO3Ca0.5
Molecular Weight 334.44
Flash Point 268ºC
PSA 102.45000
LogP 5.59450
Vapour Pressure 1.27E-11mmHg at 25°C
Storage condition room temp
Hazard Codes Xi
Risk Phrases R36/37/38
Safety Phrases 36
RIDADR NONH for all modes of transport
HS Code 2942000000
HS Code 2942000000
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:145525-41-3 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 145525-41-3 | Chemsrc address: https://www.chemsrc.com/en/baike/895530.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved